Separately, Northland Securities restated a corporate rating on shares of ValiRx Plc in a research note on Tuesday, June 7th.
ValiRx Plc (LON:VAL) opened at 9.01 on Wednesday. The stock’s 50 day moving average price is GBX 7.47 and its 200-day moving average price is GBX 8.78. ValiRx Plc has a 12-month low of GBX 5.75 and a 12-month high of GBX 29.80. The stock’s market capitalization is GBX 4.72 million.
About ValiRx Plc
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.
Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with MarketBeat.com's FREE daily email newsletter.